ArticleDiscover oncology2026
The prognostic value of miR-127-5p in cervical squamous cell carcinoma and its role in suppressing malignant behavior of cancer cells via SNX10 inhibition.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCervical squamous cell carcinoma (CESC) is the most common pathological type of cervical cancer. This study aimed to investigate the clinical relevance and functional role of miR-127-5p in CESC.
methodThis study analyzed miR-127-5p expression in tumor and paired adjacent tissues from 134 CESC patients, and evaluated its association with clinicopathological features and prognosis using Kaplan-Meier and Cox regression analyses. The effects of miR-127-5p on cell functions were assessed by CCK-8 and Transwell assays, and its interaction with SNX10 was investigated using dual-luciferase and rescue experiments.
resultsIn CESC tissues, miR-127-5p was significantly downregulated and this downregulation correlated with advanced FIGO stage and positive lymph node metastasis. Kaplan-Meier analysis showed that patients in the low miR-127-5p expression group had a lower 5-year survival rate. Cox regression analysis indicated that miR-127-5p is an independent factor affecting patient prognosis. Overexpression of miR-127-5p suppressed CESC cell proliferation, migration, and invasion by directly targeting the 3'UTR of SNX10, with rescue experiments identifying SNX10 as a key functional mediator that regulates EMT and autophagy-related pathways.
conclusionsmiR-127-5p is lowly expressed in CESC and can serve as a potential prognostic biomarker. MiR-127-5p may inhibit the malignant behavior of CESC cells by targeting SNX10.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.